FASTinov is a Startup located at Faculdade de Medicina da Universidade do Porto (FMUP), holds a patented disruptive technology to perform fast and reliable antimicrobial susceptibility tests in acute care settings. The methodology is faster than the conventional ones and identifies a broad panel of microorganisms and resistance mechanisms, directly from biological samples. The new FASTinov kit allows an automatized analysis and also provides information for the best use of antibiotics. This technology is effective for the determination of a susceptibility profile in clinically useful time and for the resistance mechanisms involved. FASTinov approach is based on the determination of the susceptibility phenotype, from positive blood cultures, within 2 hours, by flow cytometry. FASTinov speaker is Cidália Pina Vaz, co-founder of the company, who is also Full Professor at FMUP, Physician and Hospital Assistant graduated in Clinical Pathology at Hospital de São João.